U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
March-28-2017
Last Update:
April-08-2021
FDA-Approved Indications
DUPIXENT (dupilumab) is an interleukin-4 receptor alpha antagonist indicated:
For the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids;
As an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma;
As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).